Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
767.51-
QQQ
716.70-
BTC/USD
78754.500.246%
DIA
532.04-
GLD
408.23-
TLT
82.38-

Aldeyra Therapeutics Inc

ALDXNASDAQ
Trade with Public
Trade with Public
$1.48
At close: Sep 1, 5:00 PM EST
$1.56
0.085.41%
After Hours: 5:48 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Aldeyra Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aldeyra Therapeutics (ALDX).

Price Target Range — 7 Quarters

Analyst Consensus — 4 Analysts

3Buy
1Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$7Upside to Avg. PT+364.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Mar 18, 2026HC Wainwright & Co.Matthew CaufieldDowngradeBuy→Neutral$10→$2
Nov 10, 2025BTIGThomas ShraderMaintainedBuy$9
More with Benzinga EdgeGet Access

Analyst Ratings News

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded CF, ALDX, TTD, TME and DUOL. Check their ratings and price targets. Interested in TTD? See what analysts say.
Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2

HC Wainwright & Co. analyst Matthew Caufield downgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Buy to Neutral and lowers the price target from $10 to $2.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
BTIG Maintains Buy on Aldeyra Therapeutics, Lowers Price Target to $9

BTIG analyst Thomas Shrader maintains Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and lowers the price target from $11 to $9.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved